RAC media coverage, page-2217

First 2217 Last

Share
Profile

Follow
asx11

3,570 Posts.

381

20/06/24

19:50

Post #: 74414224
Share

Originally posted by ReNova: ↑

For those who are worried about the end of 2026 for recruiting timeline.

Hey chatGPT are there any examples of oncology drugs that have been bought out straight after preliminary data in a open label phase 1 clinical trial has been released?

ChatGPT: Yes, there are several examples of oncology drugs that have been acquired after promising preliminary data from open-label Phase 1 clinical trials. Pharmaceutical companies often seek to acquire innovative cancer therapies early in their development based on encouraging early-stage data. Here are a few notable examples:

Loxo Oncology and Bayer:
Drug: LOXO-292 (later named selpercatinib)
Acquisition: Loxo Oncology was acquired by Eli Lilly for approximately $8 billion in 2019, following promising early clinical data, including Phase 1 results.
Details: LOXO-292 showed promising activity against RET fusion-positive cancers in Phase 1 trials, attracting significant interest and leading to the acquisition.

Juno Therapeutics and Celgene:
Drug: JCAR017 (later named lisocabtagene maraleucel or liso-cel)
Acquisition: Celgene acquired Juno Therapeutics for $9 billion in 2018.
Details: The acquisition was driven by positive early-stage data from open-label trials showing the efficacy of JCAR017, a CAR T-cell therapy, in treating B-cell malignancies.

ArQule and Merck:
Drug: ARQ 531
Acquisition: Merck acquired ArQule for $2.7 billion in 2019.
Details: ARQ 531, a BTK inhibitor, showed promising results in Phase 1 trials for treating B-cell malignancies, prompting Merck to make the acquisition.

Immunomedics and Gilead Sciences:
Drug: Sacituzumab govitecan (Trodelvy)Acquisition: Gilead Sciences acquired Immunomedics for $21 billion in 2020.
Details: Early Phase 1/2 data showed significant efficacy in triple-negative breast cancer, leading to the acquisition.

These acquisitions illustrate the high value placed on early promising data in the oncology field and the strategic importance of acquiring innovative therapies to strengthen pharmaceutical companies' oncology portfolios.

I have not checked the details, apparently AI can hallucinate, but the response is encouraging nonetheless.

Expand

Cool story. Have you seen the RAC market cap? Getting bought out at prelim data would be a big L.

Last edited by asx11: 20/06/24

RAC Price at posting: $1.87 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

MTL

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

HIQ

HIT IQ has US patent for concussion management tech approved

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

KSN

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

AIZ

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

There are more pages in this discussion • 69 more messages in this thread...

First 2217 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.58		Change -0.025(1.56%)		Mkt cap ! $272.6M

Open	High	Low	Value	Volume
$1.69	$1.69	$1.55	$425.8K	264.9K

Buyers (Bids)

No.	Vol.	Price($)
2	7862	$1.58

Sellers (Offers)

Price($)	Vol.	No.
$1.61	2500	1

View Market Depth

No.	Vol.	Price($)
2	7862	1.580
1	1200	1.565
3	3875	1.560
2	3169	1.550
1	400	1.540

Price($)	Vol.	No.
1.610	2500	1
1.620	3588	1
1.650	11418	2
1.655	1069	1
1.660	1602	1

Last trade - 12.14pm 30/07/2024 (20 minute delay)

RAC (ASX) Chart

RAC media coverage, page-2217

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

HIT IQ has US patent for concussion management tech approved

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

RAC media coverage, page-2217

Top Stories

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

HIT IQ has US patent for concussion management tech approved

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News